Bristol Myers Squibb Reports Five-Year CheckMate-142 Data for Opdivo in MSI-H Colorectal Cancer

Bristol Myers Squibb today presented five-year follow-up data from the CheckMate-142 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with MSI-H/dMMR metastatic colorectal cancer. The data showed that 44% of patients remained alive at five years, with durable responses observed in patients who achieved complete responses.